创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

周小红, 钟诗龙. 心血管疾病常用药的药物基因组学最新研究进展[J]. 药学进展, 2018, 42(4): 269-283.
引用本文: 周小红, 钟诗龙. 心血管疾病常用药的药物基因组学最新研究进展[J]. 药学进展, 2018, 42(4): 269-283.
ZHOU Xiaohong, ZHONG Shilong. Research Progress in the Pharmacogenomics of Common Cardiovascular Drugs[J]. Progress in Pharmaceutical Sciences, 2018, 42(4): 269-283.
Citation: ZHOU Xiaohong, ZHONG Shilong. Research Progress in the Pharmacogenomics of Common Cardiovascular Drugs[J]. Progress in Pharmaceutical Sciences, 2018, 42(4): 269-283.

心血管疾病常用药的药物基因组学最新研究进展

Research Progress in the Pharmacogenomics of Common Cardiovascular Drugs

  • 摘要: 心血管疾病是人类最主要的死亡原因之一,也是消耗巨大医疗资源的疾病之一。合理药物治疗是心血管疾病治疗的基石,但是心血管疾病治疗药物的疗效和安全性存在较大个体差异。重点讨论一些证据比较明确的基因变异对β阻滞剂、他汀类药物、氯吡格雷、阿司匹林、华法林、抗心律失常药、噻嗪类利尿药的药动学、药效学以及临床终点事件和毒副反应的影响。综述心血管疾病常用药在药物基因组学方面的最新研究进展,为基于基因检测的个体化用药提供参考。

     

    Abstract: Cardiovascular disease is one of the most important causes of death and consumes huge medical resources.Rational drug therapy is the cornerstone of the treatment of cardiovascular disease, but there are significant individual differences in the efficacy and safety of cardiovascular drugs.This article focuses on the effects of some relatively well-documented gene mutations on the pharmacokinetics, pharmacodynamics, clinical endpoint and side effects of beta blockers, statins, clopidogrel, aspirin, warfarin, antiarrhythmic agents, and piperazine diuretics.The latest research progress in the pharmacogenomics of cardiovascular drugs was reviewed, providing reference for genome sequencing-based personalized medicine.

     

/

返回文章
返回